A small T-score gap separates MDS from controls
The paper's central measurement is the T-score, which expresses bone mineral density from a DXA scan relative to a young reference population; lower values mean thinner bone, and the WHO cutoffs used here are osteoporosis below −2.5, osteopenia between −1 and −2.5, and normal above −1. The authors report the femoral neck T-score only, because hip osteoarthritis can inflate total-hip readings and spinal degeneration made some lumbar scans unreadable.
At baseline, the median femoral neck T-score was −1.2 in the 111 patients with MDS and −1.0 in the 84 age-matched controls, a difference of −0.2 that was statistically significant. The gap came from the distribution of severe readings rather than a uniform shift: 12 patients with MDS had osteoporotic T-scores versus none of the controls.
That comparison is cross-sectional and observational, so it shows an association between MDS and lower bone density, not that MDS causes bone loss. The control group also differed in composition, with 55% women versus 36% in the MDS cohort, which is why the authors stratified by sex before drawing conclusions.
Women with MDS carry the baseline difference
Splitting the cohorts by sex localized the signal. Women with MDS had a median T-score 0.3 lower than control women, whereas men with MDS showed no significant difference from male controls. Because osteoporosis is more common in women and the control group contained more women, this stratification was necessary to avoid misreading the overall comparison.
The authors note that the absence of osteoporosis in the control cohort at the femoral neck may partly reflect age: the median age of male controls was 68, and osteoporosis is uncommon in men in their early seventies. They also acknowledge that hip osteoarthritis could mask low readings at that site, although both hips were evaluated to limit this bias.
Bone turnover markers did not separate the groups in the same way. CTX-I, a resorption marker, and osteocalcin, a formation marker, were comparable between patients and controls, while bone-specific alkaline phosphatase, a mineralization marker, was 27% lower in MDS. Albumin-adjusted calcium was 4% lower in MDS, though median values stayed within the normal range, and phosphate, PTH, and vitamin D did not differ.
Calcium and phosphate track T-scores only in MDS
Linear regression within the MDS cohort linked lower calcium to higher T-scores (β −3.56) and higher phosphate to higher T-scores (β 1.66), and both associations survived adjustment for age, sex, MDS duration, IPSS-M risk score, and transfusion dependence. The same bone parameters showed no influence on T-scores in controls.
The direction of the calcium result is counterintuitive, and the authors treat it as such: they describe low calcium as appearing advantageous in MDS and connect the combination of low calcium with reduced bone-specific alkaline phosphatase to impaired bone matrix mineralization. That mechanism is a hypothesis, and the paper states that histomorphometric analysis would be needed to confirm it.
Because these are regression estimates from a single cohort, they describe how serum markers co-vary with T-scores, not what changing calcium or phosphate would do to bone. The associations also cannot be transferred to people without MDS, since the control analysis found no such relationships.
DNMT3A mutation marks lower bone density inside MDS
Among the mutations tested, DNMT3A stood out: the 20 patients carrying it had T-scores 0.7 lower than patients without it. The same mutation had no effect on T-scores in the 25 controls with clonal hematopoiesis of indeterminate potential, and DNMT3A carriers had red cell counts and bone serum markers similar to non-carriers, so the difference was not explained by those factors.
The pattern was not uniform across genes. A variant allele frequency above 10% in ASXL1 was associated with higher T-scores, by 0.9, which runs opposite to the DNMT3A direction. The IPSS-M risk score itself was not associated with T-scores, so the molecular link appears specific to particular mutations rather than to overall disease risk.
These subgroup comparisons rest on small numbers, and the variant allele frequency analysis found no difference when patients were split at the 10% threshold. The DNMT3A finding should therefore be read as a hypothesis-generating association within this cohort rather than an established risk marker.
T-scores fell over three years in a small sample
The longitudinal component is the study's main advance over prior retrospective work, but attrition was severe. Only 23 patients with MDS and 7 controls returned for the three-year DXA, and after excluding those who started osteoporosis therapy or missed the scan, 18 patients with MDS were analyzable; 5 of the 7 controls had received bisphosphonates or denosumab, which the authors judged to preclude meaningful comparison.
In those 18 patients, femoral neck T-scores fell by 0.3 from baseline, while red cell counts and serum calcium, bone-specific alkaline phosphatase, and phosphate stayed unchanged. At baseline none of the 18 had osteoporosis, 9 had osteopenia, and 9 had normal T-scores; after three years, 1 had osteoporosis, 9 had osteopenia, and 8 had normal T-scores.
Quality of life, measured with the EORTC QLQ-C30, was lower in patients with MDS than controls and remained stable across the three years even as T-scores declined. The authors attribute the limited follow-up to death, loss to follow-up, allogeneic stem cell transplantation, and visits scheduled after study termination, so the 0.3 decline describes a selected surviving subgroup rather than the full MDS cohort.
Osteoporosis accompanies poorer survival in MDS
In the survival analysis, 33 of the 111 baseline patients were excluded because of stem cell transplantation or follow-up scheduled after study termination. Among the remainder, 31 had normal T-scores, 39 had osteopenia, and 8 had osteoporosis, and the presence of osteoporosis was associated with poorer overall survival.
This is a prognostic association, not evidence that bone loss worsens MDS. The osteoporotic group contained only 8 patients, and the analysis cannot separate bone density from the age, comorbidity, or disease severity that accompany it.
Falls and fractures pointed in an unexpected direction: 23% of controls reported a fall and 19% a previous fracture, versus 6% and 6% of patients with MDS. The authors suggest this may reflect cautious mobility in patients with MDS or gait instability from osteoarthritis in controls, and they note that the events were self-reported and the subgroup too small for firm conclusions.
Which MDS patients most warrant a DXA scan
The paper's practical claim is that bone health belongs in the diagnostic work-up and clinical management of MDS. The evidence supports directing that attention most strongly to women with MDS, who carried the baseline deficit, and to patients carrying a DNMT3A mutation, who had the largest within-cohort T-score gap.
The survival finding adds a second reason to identify osteoporosis once it is present, since the osteoporotic group had poorer overall survival. The authors frame DXA as a way to detect osteoporosis early and to prompt lifestyle counseling, supplementation, or osteoporosis therapy, but they do not test whether any of these interventions changes outcomes in MDS.
Two boundaries limit how far the screening argument travels. The three-year decline rests on 18 patients, and the two study sites did not perform cross-calibration phantom scans to adjust for differences between DXA machines, although daily phantom quality control confirmed stable measurements at each site. The case for screening is therefore strongest where the baseline data are strongest: women with MDS and DNMT3A-mutated patients, with the longitudinal trajectory still awaiting confirmation in a larger cohort.
Sources used in this answer
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Patients with MDS had lower femoral neck T-scores than age-matched controls, driven mainly by women with MDS; DNMT3A mutation was associated with a 0.7-lower T-score within the MDS cohort, T-scores declined by 0.3 over three years in 18 re-measured patients, and osteoporosis was associated with poorer overall survival.
